The hexapeptide Ac-RYYRWK-NH2 has garnered significant attention in the field of neuropharmacology due to its interaction with the nociceptin/orphanin FQ (N/OFQ) receptor, also known as the ORL1 receptor. This receptor is a G protein-coupled receptor (GPCR) that plays a crucial role in various physiological processes, including pain modulation, cardiovascular function, and stress response. Understanding the mechanism of action and potential applications of Ac-RYYRWK-NH2 can provide insights into the development of new therapeutic agents for treating a range of conditions.
Ac-RYYRWK-NH2 and its analogs have been explored as potential analgesic and antineuropathic drugs. The peptide library-based antagonist Ac-RYYRIK-NH2, which shares a similar sequence with Ac-RYYRWK-NH2, inhibits nociceptin activity mediated through ORL1 receptors, indicating its potential for pain management5. Modifications to the peptide structure have led to analogs with enhanced receptor-binding affinity and strong antagonist activity, which could be more potent in clinical applications5.
The ability of Ac-RYYRWK-NH2 to fully inhibit the chronotropic effect of nociceptin on cardiomyocytes points to its potential application in cardiovascular research. By antagonizing nociceptin's action, it may be possible to modulate heart rate and other cardiac functions, which could be beneficial in the treatment of certain cardiovascular diseases1.
In neuropharmacological studies, Ac-RYYRWK-NH2 has been used to investigate the role of the nociceptin receptor in various central nervous system (CNS) functions. For instance, the ligand has been shown to affect spontaneous locomotor activity in mice, suggesting its influence on motor control and behavior4. Additionally, the regional distribution of [3H]ac-RYYRWK-NH2 binding in rat brain sections correlates with that of nociceptin, indicating its relevance in studying brain function and disorders2.
The structural requirements for receptor binding of Ac-RYYRWK-NH2 have been extensively studied, providing valuable information for the design of new therapeutic agents targeting the ORL1 receptor. The importance of the N-terminal acetyl group and the C-terminal amide group has been highlighted, as well as the significance of the N-terminal Arg residue8. These insights can guide the development of more selective and potent drugs with fewer side effects.
Ac-RYYRWK-NH2 has been characterized as a potent partial agonist at the nociceptin receptor, with high specificity and no affinity for other opioid receptors such as µ-, κ-, or δ-opioid receptors2. It has been shown to competitively antagonize the effects of nociceptin, a neuropeptide that acts as a hyperalgesic agent, by inhibiting G protein activation in rat brain preparations1. Furthermore, Ac-RYYRWK-NH2 has been radiolabelled to create [3H]ac-RYYRWK-NH2, which has been used in receptor-binding experiments to reveal a single high-affinity site for the ligand in rat cortical membranes2. This ligand has also been shown to inhibit the chronotropic effect of nociceptin on neonatal rat cardiomyocytes, suggesting its potential as a starting point for the development of specific antagonists1.
CAS No.: 211230-67-0
CAS No.: 108102-98-3
CAS No.: 105879-63-8
CAS No.: 126247-74-3
CAS No.: 88166-21-6
CAS No.: 5291-26-9